pyrroles has been researched along with Myocardial Ischemia in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 42 (35.29) | 18.2507 |
| 2000's | 54 (45.38) | 29.6817 |
| 2010's | 21 (17.65) | 24.3611 |
| 2020's | 2 (1.68) | 2.80 |
| Authors | Studies |
|---|---|
| Ansari, H; Barekat, M; Mahmoudi, E; Pahlavan, S; Parchehbaf-Kashani, M; Rajabi, S; Sepantafar, M | 1 |
| Deguchi, H; Sugano, K; Tsujita, K; Uda, A | 1 |
| Chrysohoou, C; Dilaveris, P; Kioufis, S; Maniatis, K; Michalea, S; Miliou, A; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tousoulis, D; Zaromitidou, M | 1 |
| Bianchi, C; Chu, LM; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Bianchi, C; Chu, LM; Dalal, RS; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Athanasiou, D; Chrysohoou, C; Hatzis, G; Mazaris, S; Mourouzis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tourikis, P; Tousoulis, D; Zaromitidou, M; Zisimos, K | 1 |
| Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A | 1 |
| Gromnaky, NI; Mikhin, VP; Zhilyaeva, YA | 1 |
| Climent, VE; Lip, GY; López-Cuenca, A; Marín, F; Roldán, V; Valdés, M | 1 |
| Császár, A | 1 |
| Braunwald, E; Cannon, CP; Giraldez, RR; Giugliano, RP; McCabe, CH; Mohanavelu, S; Murphy, SA | 1 |
| Kukhrchuk, VV; Nasonov, EL; Novikova, DS; Popkova, TV; Tutunov, VS | 1 |
| Karadağ, B; Ongen, Z; Yilmaz, Y | 1 |
| Ageev, FT; Kulev, BD | 1 |
| Arandarcikaite, O; Barauskaite, J; Borutaite, V; Brown, GC; Jekabsone, A; Morkuniene, R | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Chang, SA; Kim, DH; Kim, HK; Kim, YJ; Oh, BH; Park, YB; Sohn, DW | 1 |
| Colivicchi, F; Genovesi Ebert, A; Melina, G; Mocini, D; Santini, M; Strano, S; Tubaro, M; Uguccioni, M | 1 |
| Abuladze, GV; Dundua, GI; Dzhindzholiia, NR; Nebieridze, MI | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Dereli, Y; Ege, E; Kurban, S; Sarigül, A | 1 |
| Kukes, IV; Paukov, SV; Ruvinov, IuV; Sivkov, AS | 1 |
| Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Ozova, EM | 1 |
| Azizova, OA; Baranova, OA; Blagodatskikh, KA; Koroleva, OS; Nosikov, VV; Pushkov, AA; Reznichenko, NE; Zateĭshchikov, DA | 1 |
| Bao, W; Benessiano, J; Mallat, Z; Olsson, AG; Ryu, SK; Schwartz, GG; Tedgui, A; Tsimikas, S | 1 |
| Wang, H; Ye, P; Zhang, JY | 1 |
| Lazareva, NV; Oshchepkova, EV | 1 |
| Chu, LM; Elmadhun, NY; Feng, J; Lassaletta, AD; Liu, Y; Sellke, FW | 1 |
| Supanich, B | 1 |
| Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A | 1 |
| Bell, RM; Yellon, DM | 1 |
| Buller, N; Casciano, R; Doyle, J; Gillen, D; Wilson, K | 1 |
| Correia, LC; D'Oliveira, A; Esteves, JP; Magalhães, LP; Passos, LC; Rocha, MS; Santana, O; Spósito, AC | 1 |
| Bao, Y; Bernard, SA; Lazar, HL; Zhang, Y | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Julier, K; Mackness, MI; Neil, HA; Soedamah-Muthu, SS; Thomason, MJ | 1 |
| Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI | 1 |
| Belousov, IuB; Leonova, MV | 1 |
| Arikian, S; Ganz, P; Schwartz, GG; Waters, D | 1 |
| Arsenault, M; Auclair, L; Bogaty, P; Boyer, L; Dagenais, GR; Jobin, J; Pépin, G; Poirier, P | 1 |
| Gathof, BS; Gresser, U | 1 |
| Carlson, W; Clark, ME; Creager, M; Frei, B; Johnstone, M; Kinlay, S; Lloyd-Jones, DM; Maccallum, G; Orav, J; Rubenstein, J; Selwyn, AP; Sopko, G; Stone, PH | 1 |
| Carlier, M; Claeys, MJ; Cools, F; Cosyns, B; De Meester, A; Dewit, B; Gobin, E; Hoffer, E; Missault, L; Vermeersch, P | 1 |
| Daemen, MJ; Dassen, WR; De Windt, LJ; Doevendans, PA; Heeneman, S; Palmen, M; Van Bilsen, M; Willems, J; Zimmermann, R | 1 |
| McGowan, MP | 1 |
| Davidson, MH | 1 |
| Deedwania, PC | 1 |
| Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Waters, D; Zeiher, A | 1 |
| Andrews, TC; Carlson, W; Cole, H; Creager, MA; Frei, B; Johnstone, M; Kinlay, S; Lloyd-Jones, DM; Orav, J; Rubenstein, J; Selwyn, AP; Sopko, G; Stone, PH | 1 |
| Ahn, JY; Choi, IS; Chung, WJ; Han, SH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK | 1 |
| Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Fonarow, GC | 1 |
| Babkin, AA; Iliukhin, OV; Kalganova, EL; Lopatin, IuM | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Brown, BG | 1 |
| Bianchi, C; Boodhwani, M; Feng, J; Laham, R; Li, J; Mieno, S; Nakai, Y; Ramlawi, B; Sellke, FW; Voisine, P | 1 |
| Cerletti, C; Dell'Elba, G; Evangelista, V; Manarini, S; Rotondo, S | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Yamagishi, M | 1 |
| Birnbaum, Y; Huang, MH; Lin, Y; Lui, CY; Martinez, JD; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D | 1 |
| Gotto, AM | 1 |
| Jamieson, MJ; Luo, D; Olsson, AG; Schwartz, GG; Szarek, M | 1 |
| Prigent, B | 1 |
| Ezhov, MV; Kukharchuk, VV; Naumov, VG; Samoĭlenko, EIu; Sergienko, IV; Tvorogova, MG | 1 |
| Balakhonova, TV; Kukharchuk, VV; Kulev, BD; Masenko, VP; Pogorelova, OA; Rogozova, AN; Rozhkova, TA; Susekov, AV; Tripoten', MI; Zubareva, MIu | 1 |
| Braunwald, E | 1 |
| Arca, M; Gaspardone, A | 1 |
| Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z | 1 |
| Boodhwani, M; Clements, RT; Feng, J; Mieno, S; Sellke, FW; Sodha, NR; Xu, SH | 1 |
| Garner, J; Gould, KL; McLain, R; Sdringola, S; Zamarka, LG | 1 |
| Ameliushkina, VA; Kaminnyĭ, AI; Korotaeva, AA; Kucharchuk, VV; Naumov, VG; Pirkova, AA; Prokazova, NV; Samoĭlova, EV; Titov, VN | 1 |
| Curtis, MJ; Hearse, DJ; Rees, SA; Tsuchihashi, K | 1 |
| Kinoshita, M; Nakae, I; Quan, L; Sugimoto, Y; Tsutamoto, T | 1 |
| Grover, GJ; Speechly-Dick, ME; Yellon, DM | 1 |
| Abe, T; Arita, M; Saikawa, T; Sakata, T; Sato, T; Shigematsu, S | 1 |
| D'Alonzo, AJ; Darbenzio, RB; Grover, GJ; Parham, CS | 2 |
| Atwal, KS; D'Alonzo, AJ; Grover, GJ; McCullough, JR; Sargent, CA | 1 |
| Dux, L; Ferdinandy, P; Koltai, M; Szilvássy, Z | 1 |
| Grover, GJ | 2 |
| D'Alonzo, AJ; Darbenzio, RB; Grover, GJ; Hess, TA; Sewter, JC; Sleph, PG | 1 |
| Moore, TL; Shebuski, RJ; Toombs, CF | 1 |
| Armstrong, JM; Bellemin-Baurreau, J; Hicks, PE; Poizot, A; Rochette, L | 1 |
| Hellwig, B | 1 |
| Cavero, I; Premmereur, J | 1 |
| Allard, M; Braquet, PG; Ferdinandy, P; Jakab, I; Koltai, M; Lonovics, J; Szilvassy, Z; Tarrade, T | 1 |
| Ahmed, SZ; Atwal, KS; Dzwonczyk, S; Ferrara, FN; Grover, GJ; Harper, TW; Kim, KS; Moreland, S; Russell, AD; Sleph, PG | 1 |
| Das, DK; Engelman, RM; Szerdahelyi, P; Tosaki, A | 1 |
| Nakaya, H | 1 |
| Harada, K; Jinno, Y; Miwa, A; Nakazawa, H; Nishikori, K; Ogawa, N; Ohta, H | 1 |
| Das, DK; Engelman, DT; Engelman, RM; Tosaki, A | 1 |
| D'Alonzo, AJ; Darbenzio, RB; Grover, GJ; Hess, T; Sleph, PG | 1 |
| Droy-Lefaix, MT; Ferdinandy, P; Koltai, M; Szilvássy, Z; Tarrade, T | 1 |
| Grover, GJ; Sleph, PG | 1 |
| Baird, AJ; Grover, GJ; Sleph, PG | 1 |
| Dzwonczyk, S; Grover, GJ; Monticello, TM | 1 |
| D'Alonzo, AJ; Darbenzio, RB; Grover, GJ; Hess, TA; Lodge, NJ; Normandin, DE; Sewter, JC; Sleph, PG | 1 |
| Das, DK; Engelman, RM; Tosaki, A | 1 |
| Chujo, M; Hori, M; Inoue, M; Kamada, T; Kitakaze, M; Komamura, K; Minamino, T; Mori, H; Node, K; Shinozaki, Y | 1 |
| Escande, D; Henry, P; Hinescu, ME; Popescu, A; Pucéat, M | 1 |
| Fleck, E; Henning, B; Hildebrandt, AG; Ott, T; Zünkler, BJ | 1 |
| Deslauriers, R; Docherty, JC; Gunter, HE; Kuzio, B; Shoemaker, L; Yang, L | 1 |
| Das, DK; Tosaki, A | 1 |
| Black, D; Chaitman, BR; Ezekowitz, MD; Ganz, P; Kane, JP; Oliver, MF; Olsson, AG; Pressler, ML; Schwartz, GG; Texter, M; Waters, D | 1 |
| Brown, WV; Eisenberg, D; McCormick, LS; Pitt, B; Schwartz, L; Shurzinske, L; Title, LM; van Boven, AJ; Waters, D | 1 |
| Baim, DS; Carrozza, JP; Cohen, DJ | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Blumenthal, RS; Cohn, G; Schulman, SP | 1 |
| Hideg, K; Kalai, T; Kuppusamy, P; Li, H; Xu, KY; Zhou, L; Zweier, JL | 1 |
| Kitano, M; Matsui, K; Ohashi, N; Sasabe, M; Yamamoto, S | 1 |
| Scheen, AJ | 1 |
| Puel, J | 1 |
| de la Iglesia Martínez, F; Diz-Lois Martínez, F; Nicolás Miguel, R; Pellicer Vázquez, C; Pita Fernández, S; Ramos Polledo, V | 1 |
| Alexander, S; Bilodeau, T; Carlson, W; Clark, M; Johnstone, M; Karam, C; Kinlay, S; Lloyd-Jones, DM; Orav, J; Ridker, PM; Rifai, N; Rubenstein, J; Stone, PH; Timms, T | 1 |
| de Hemptinne, A; Vanheel, B | 1 |
| Galiñanes, M; Hearse, DJ; Shattock, MJ | 1 |
| Wilde, AA | 1 |
| Alexander, LD; Lamp, ST; Stuart, JS; Venkatesh, N; Weiss, JN | 1 |
12 review(s) available for pyrroles and Myocardial Ischemia
| Article | Year |
|---|---|
[Important aim of statin therapy: ischemic cardiovascular event (stroke)].
Topics: Acute Disease; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Ischemia; Pyrroles; Recurrence; Stroke | 2008 |
[Atorvastatin in secondary prevention].
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Secondary Prevention; Stroke | 2009 |
[Efficacy of atorvastatin in long-term treatment of patients with ischemic heart disease].
Topics: Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2003 |
Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2004 |
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome | 2005 |
Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
Topics: Angioplasty, Balloon; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Myocardial Ischemia; Pyrroles | 2007 |
Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dihydropyridines; Disease Models, Animal; Dogs; Guanidines; Guinea Pigs; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Picolines; Pinacidil; Potassium Channels; Pyrans; Pyrroles; Rats; Vasodilator Agents | 1994 |
[Potassium agonists].
Topics: Animals; Benzopyrans; Calcium; Cromakalim; Humans; Membrane Potentials; Muscle, Smooth, Vascular; Myocardial Ischemia; Neuromuscular Junction; Niacinamide; Nicorandil; Potassium; Potassium Channels; Pyrroles; Vascular Resistance; Vasodilator Agents | 1994 |
[Potential role of ATP-sensitive K+ channels in ischemia- and reperfusion-induced arrhythmias].
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Benzopyrans; Cromakalim; Glyburide; Guanidines; Humans; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Niacinamide; Nicorandil; Pinacidil; Potassium; Potassium Channels; Pyrroles; Tolbutamide | 1993 |
Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion.
Topics: Animals; ATP-Binding Cassette Transporters; Benzopyrans; Cromakalim; Guanidines; Humans; Ischemic Preconditioning, Myocardial; KATP Channels; Mitochondria, Heart; Models, Cardiovascular; Myocardial Ischemia; Myocardial Reperfusion; Niacinamide; Nicorandil; Picolines; Pinacidil; Potassium Channels; Potassium Channels, Inwardly Rectifying; Pyrans; Pyrroles; Rats | 1997 |
Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Myocardial Ischemia; Myocardial Revascularization; Pyrroles; Randomized Controlled Trials as Topic | 2000 |
[Statins and unstable angina: MIRACL].
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles | 2001 |
34 trial(s) available for pyrroles and Myocardial Ischemia
| Article | Year |
|---|---|
Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure.
Topics: Aged; Arteries; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Pyrroles; Regression Analysis; Ventricular Remodeling | 2013 |
Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Atorvastatin; Biomarkers; Brachial Artery; Cell Movement; Cross-Over Studies; Double-Blind Method; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Glycoproteins; Greece; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Myocardial Ischemia; Peptides; Pyrroles; Recovery of Function; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor Receptor-2; Vasodilation | 2015 |
Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 1; Myocardial Ischemia; Pyrroles; Risk Factors; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2010 |
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Pravastatin; Pyrroles; Treatment Outcome | 2008 |
[Comparative assessment of antiinflammatory action of atorvastatin in ischemic heart disease and rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyrroles; Treatment Outcome | 2008 |
[Effect of various approaches to therapy with statins in high risk patients from the point of view of vascular endothelium].
Topics: Aged; Atorvastatin; Brachial Artery; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Vasodilation | 2009 |
Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Stenosis; Cerebrovascular Disorders; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
Persistent regional diastolic dysfunction after myocardial ischemia and the effect of statin treatment: assessment with two-dimensional radial strain rate.
Topics: Angina Pectoris, Variant; Atorvastatin; Diastole; Exercise Test; Female; Fluorobenzenes; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrimidines; Pyrroles; Reference Standards; Rosuvastatin Calcium; Sulfonamides; Ultrasonography; Ventricular Dysfunction, Left | 2010 |
Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Italy; Male; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvastatin; Blood Pressure; C-Reactive Protein; Carbazoles; Carvedilol; Chronic Disease; Drug Therapy, Combination; Elasticity; Female; Heart Failure; Heptanoic Acids; Humans; Interleukin-6; Male; Metoprolol; Middle Aged; Myocardial Ischemia; Propanolamines; Pyrroles; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Resistance | 2011 |
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome | 2002 |
A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Endpoint Determination; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Treatment Outcome; United Kingdom | 2003 |
Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2003 |
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myocardial Ischemia; Patient Compliance; Probability; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2003 |
Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris.
Topics: Aged; Angina, Unstable; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Pyrroles | 2003 |
Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Regional Blood Flow; Ultrasonography; Vasodilation; Vitamin E | 2004 |
Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease.
Topics: Aged; Angina Pectoris; Atorvastatin; Cholesterol, LDL; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Ischemia; Pyrroles; Time Factors | 2004 |
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment | 2004 |
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Myocardial Infarction; Myocardial Ischemia; Prognosis; Proportional Hazards Models; Pyrroles; Recurrence | 2005 |
Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
Topics: Angina Pectoris; Antioxidants; Ascorbic Acid; Atorvastatin; Coronary Artery Disease; Diet Therapy; Dose-Response Relationship, Drug; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Myocardial Ischemia; Pyrroles; Vasomotor System; Vitamin E | 2005 |
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Topics: Arteriosclerosis; Atorvastatin; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome; Ultrasonography | 2005 |
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Topics: Acute Disease; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Metabolic Syndrome; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Pyrroles; Recurrence; Risk Factors; Treatment Outcome | 2005 |
[Changes of elastic properties of magistral arteries in patients with ischemic heart disease during treatment with atorvastatin and simvastatin].
Topics: Anticholesteremic Agents; Arteries; Atorvastatin; Carotid Arteries; Cholesterol; Data Interpretation, Statistical; Elasticity; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Myocardial Ischemia; Pyrroles; Radial Artery; Simvastatin; Time Factors; Triglycerides | 2005 |
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Myocardial Ischemia; Pyrroles; Quinolines; Research Design; Syndrome | 2006 |
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pravastatin; Pyrroles; Sex Characteristics | 2007 |
Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome | 2007 |
[Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Myocardial Ischemia; Postprandial Period; Pyrroles; Treatment Outcome | 2007 |
[Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and stiffness of vascular wall].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles | 2007 |
A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Double-Blind Method; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Ischemia; Positron-Emission Tomography; Prospective Studies; Pyrroles | 2008 |
[Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lecithins; Lipoproteins, LDL; Lysophosphatidylcholines; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Quality of Life; Risk; Treatment Outcome | 1999 |
[Significance of the follow-up of patients with ischemic cardiopathy in the treatment with atorvastatin as secondary prevention. Pilot study].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Pilot Projects; Prospective Studies; Pyrroles | 2002 |
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lovastatin; Middle Aged; Myocardial Ischemia; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2002 |
73 other study(ies) available for pyrroles and Myocardial Ischemia
| Article | Year |
|---|---|
Heart Repair Induced by Cardiac Progenitor Cell Delivery within Polypyrrole-Loaded Cardiogel Post-ischemia.
Topics: Animals; Animals, Newborn; Cell- and Tissue-Based Therapy; Cells, Cultured; Connexin 43; Gels; Human Embryonic Stem Cells; Humans; Male; Myocardial Ischemia; Myocardium; Myocytes, Cardiac; Polymers; Pyrroles; Rats; Sheep; Tissue Engineering; Tissue Scaffolds; Troponin T; Ventricular Function, Left | 2021 |
Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study.
Topics: Aged; Asian People; Databases, Factual; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Japan; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2020 |
Differential effects of atorvastatin on autophagy in ischemic and nonischemic myocardium in Ossabaw swine with metabolic syndrome.
Topics: Animals; Atorvastatin; Autophagy; Biomarkers; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Pyrroles; Signal Transduction; Swine | 2014 |
Atorvastatin regulates apoptosis in chronically ischemic myocardium.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Developmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Neovascularization, Pathologic; Pyrroles; Swine; Swine, Miniature | 2015 |
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2015 |
[Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Ischemia; Pyrroles | 2016 |
Nitric oxide protects the heart from ischemia-induced apoptosis and mitochondrial damage via protein kinase G mediated blockage of permeability transition and cytochrome c release.
Topics: Animals; Apoptosis; Carbazoles; Cyclic GMP-Dependent Protein Kinases; Cytochromes c; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Ischemia; Nitric Oxide; Nitric Oxide Donors; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; Triazenes | 2009 |
[The efficasy of atorvastatin in the case of paroxismal atrial fibrillation in patients with ischemic heart disease].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome | 2010 |
Atorvastatin pretreatment diminishes the levels of myocardial ischemia markers early after CABG operation: an observational study.
Topics: Aged; Atorvastatin; Biomarkers; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Troponin I | 2010 |
[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
Topics: Atorvastatin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pharmacokinetics; Platelet Aggregation Inhibitors; Precision Medicine; Pyrroles; Ticlopidine | 2010 |
[Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease].
Topics: Age of Onset; Apolipoprotein A-I; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypolipidemic Agents; Kinesins; Male; Middle Aged; Myocardial Ischemia; Pharmacogenetics; Polymorphism, Genetic; Pyrroles; Simvastatin; Treatment Outcome | 2011 |
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Oxidation-Reduction; Phospholipases A2, Secretory; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Risk Factors; Survival Analysis | 2012 |
[Protective effect of atrovastatin against myocardial ischemia-reperfusion injury and on liver and kidney functions in aged rats].
Topics: Aging; Animals; Atorvastatin; Female; Heptanoic Acids; Kidney; Liver; Male; Multiple Organ Failure; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Wistar | 2012 |
What price atorvastatin?
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Risk Factors | 2012 |
[Painless myocardial ischemia in patient with extensive constrictive atherosclerosis of coronary arteries].
Topics: Angioplasty; Anticholesteremic Agents; Asymptomatic Diseases; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Echocardiography; Electrophysiologic Techniques, Cardiac; Exercise Test; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.
Topics: Angiogenesis Inducing Agents; Angiogenic Proteins; Animals; Atorvastatin; Biomarkers; Collateral Circulation; Coronary Circulation; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Metabolic Syndrome; Microvessels; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Neovascularization, Physiologic; Oxidative Stress; Pyrroles; Signal Transduction; Swine; Swine, Miniature; Vasodilation; Vasodilator Agents | 2012 |
Aggressive lipid-lowering in stable patients with coronary artery disease.
Topics: Angioplasty; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Male; Multicenter Studies as Topic; Myocardial Ischemia; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic | 1999 |
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyrroles; Reperfusion; Signal Transduction; Time Factors; Up-Regulation | 2003 |
Pretreatment with statins enhances myocardial protection during coronary revascularization.
Topics: Animals; Atorvastatin; Cardiopulmonary Bypass; Disease Models, Animal; Electric Countershock; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Myocardial Ischemia; Myocardial Revascularization; Premedication; Pyrroles; Random Allocation; Swine | 2003 |
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin | 2003 |
Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Cost-Benefit Analysis; Economics, Pharmaceutical; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Secondary Prevention; Syndrome | 2003 |
Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism.
Topics: Animals; Blotting, Western; Cell Survival; Fibroblast Growth Factor 1; Heart Ventricles; Hemodynamics; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Transgenic; Myocardial Ischemia; Myocardial Reperfusion; Precipitin Tests; Protein Kinase C; Protein-Tyrosine Kinases; Pyrroles; Receptors, Fibroblast Growth Factor; Recovery of Function; Signal Transduction | 2004 |
High-dose statins in acute coronary syndromes.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocardial Ischemia; Pyrroles; Risk; Simvastatin | 2005 |
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Pravastatin; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2004 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Angiostatins; Animals; Apoptosis; Apoptosis Inducing Factor; Arterioles; Atorvastatin; Caspase 3; Caspases; Cholesterol; Coronary Circulation; Coronary Vessels; Drug Evaluation, Preclinical; Endostatins; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinase 9; Myocardial Ischemia; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroprusside; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptor, TIE-2; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A; Vasodilation | 2006 |
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors | 2006 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Proteins; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2007 |
Statin therapy and the elderly: SAGE advice?
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Pyrroles | 2007 |
Statin wars following coronary revascularization - evidence-based clinical practice?
Topics: Atorvastatin; Canada; Drug Industry; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Myocardial Revascularization; Pyrroles | 2007 |
Reducing myocardial injury by minimizing imbalance between oxygen supply and demand.
Topics: Anesthesiology; Animals; Atorvastatin; Blood Pressure; Cardiovascular Agents; Coronary Disease; Dogs; Heart Diseases; Heart Rate; Heptanoic Acids; History, 20th Century; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Myocardial Revascularization; Necrosis; Oxygen; Pyrroles | 2007 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib | 2007 |
Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine.
Topics: Animals; Atorvastatin; Cholesterol; Collateral Circulation; Coronary Circulation; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Microcirculation; Myocardial Ischemia; Neovascularization, Physiologic; Pyrroles; Swine | 2008 |
Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats.
Topics: Animals; Anti-Arrhythmia Agents; Benzopyrans; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Coronary Circulation; Cromakalim; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Heart Rate; Hemodynamics; In Vitro Techniques; Injections, Intravenous; Male; Myocardial Ischemia; Potassium Channels; Pyrroles; Rats; Rats, Wistar; Vasodilator Agents; Ventricular Fibrillation | 1993 |
Glibenclamide-induced oscillation of canine coronary artery is independent of myocardial ischemia.
Topics: Adenosine Triphosphate; Animals; Arginine; Benzopyrans; Coronary Circulation; Coronary Vessels; Cromakalim; Diltiazem; Dogs; Female; Glyburide; In Vitro Techniques; Male; Muscle Tonus; Muscle, Smooth, Vascular; Myocardial Ischemia; Niacinamide; Nicorandil; Nitroarginine; Nitroglycerin; Potassium Channels; Pyrroles; Vasodilator Agents | 1994 |
Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model.
Topics: Adenosine Triphosphate; Adult; Aged; Alkaloids; Benzophenanthridines; Benzopyrans; Cromakalim; Diglycerides; Female; Heart Atria; Humans; In Vitro Techniques; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion; Phenanthridines; Potassium Channels; Protein Kinase C; Pyrroles; Random Allocation; Time Factors | 1995 |
Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Benzopyrans; Cromakalim; Glyburide; Guinea Pigs; Male; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardial Stunning; Myocardium; Perfusion; Potassium Channels; Pyrroles | 1995 |
Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Benzopyrans; Cromakalim; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Infusions, Intravenous; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Phenethylamines; Potassium Channels; Pyrroles; Regional Blood Flow; Sulfonamides | 1995 |
Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Aorta; Benzopyrans; Cromakalim; Decanoic Acids; Dogs; Female; Glyburide; Guanidines; Guinea Pigs; Heart; Heart Ventricles; Hydroxy Acids; In Vitro Techniques; Injections, Intravenous; Injections, Subcutaneous; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Myocardial Ischemia; Potassium Channels; Pyrroles; Rats; Rats, Sprague-Dawley; Vasodilator Agents | 1995 |
Ventricular overdrive pacing-induced preconditioning and no-flow ischemia-induced preconditioning in isolated working rat hearts.
Topics: Animals; Benzopyrans; Blood Pressure; Cardiac Pacing, Artificial; Coronary Circulation; Cromakalim; Disease Models, Animal; Glyburide; Heart; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Reperfusion Injury; Potassium Channels; Pyrroles; Rats; Rats, Wistar; Vasodilator Agents | 1995 |
Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.
Topics: Animals; Arrhythmias, Cardiac; Benzopyrans; Cromakalim; Glyburide; Guanidines; Heart; Heart Rate; Myocardial Ischemia; Myocardial Reperfusion Injury; Perfusion; Pinacidil; Potassium; Pyrroles; Rats; Rats, Sprague-Dawley; Vasodilator Agents | 1994 |
Cardioprotection with U-89232 is not reversible with glibenclamide: evidence of a novel anti-ischemic agent derived from cromakalim.
Topics: Animals; Benzopyrans; Cromakalim; Female; Glyburide; Guanidines; Heart; Hemodynamics; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Necrosis; Potassium Channels; Pyrroles; Rabbits; Vasodilator Agents | 1994 |
Effects of ATP-dependent K+ channel modulators on an ischemia-reperfusion rabbit isolated heart model with programmed electrical stimulation.
Topics: Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Benzopyrans; Blood Pressure; Coronary Circulation; Cromakalim; Electric Stimulation; Glyburide; Heart; In Vitro Techniques; Myocardial Ischemia; Myocardial Reperfusion Injury; Potassium Channels; Pyrroles; Rabbits; Refractory Period, Electrophysiological; Vasodilator Agents | 1994 |
ATP sensitive potassium channel openers are of potential benefit in ischaemic heart disease.
Topics: Benzopyrans; Cromakalim; Dihydropyridines; Guanidines; Humans; Myocardial Ischemia; Myocardium; Niacinamide; Nicorandil; Picolines; Pinacidil; Potassium Channels; Pyrans; Pyrroles; Sodium-Potassium-Exchanging ATPase; Vasodilator Agents | 1994 |
Cromakalim and cicletanine against pacing-induced myocardial ischemia in conscious rabbits.
Topics: Animals; Antihypertensive Agents; Benzopyrans; Blood Pressure; Cardiac Pacing, Artificial; Consciousness; Cromakalim; Heart Rate; Male; Myocardial Ischemia; Potassium Channels; Pyridines; Pyrroles; Rabbits; Stroke Volume; Vasodilator Agents; Ventricular Function, Left | 1994 |
Cardioselective anti-ischemic ATP-sensitive potassium channel openers.
Topics: Adenosine Triphosphate; Animals; Aorta; Benzopyrans; Biological Availability; Cocaine; Cromakalim; Guanidines; Ion Channel Gating; Molecular Structure; Myocardial Ischemia; Potassium Channels; Pyrroles; Rats; Structure-Activity Relationship; Vasodilation | 1993 |
Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Benzopyrans; Cations; Cromakalim; Glyburide; Heart; Ion Channel Gating; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Potassium Channels; Pyrroles; Rats; Rats, Sprague-Dawley | 1993 |
Effects of K+ channel openers on ischemic dysfunction and metabolic disturbance in isolated perfused rat heart.
Topics: Animals; Benzopyrans; Cromakalim; Heart; Hemodynamics; Male; Myocardial Ischemia; Myocardial Reperfusion; Pyridines; Pyrroles; Rats; Rats, Wistar; Vasodilator Agents | 1993 |
Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzopyrans; Cations; Cromakalim; Diabetes Mellitus, Experimental; Glyburide; Heart Function Tests; Hypoglycemic Agents; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Potassium Channel Blockers; Potassium Channels; Pyrroles; Rats; Rats, Sprague-Dawley; Streptozocin | 1995 |
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Female; Glyburide; Guanidines; Guinea Pigs; In Vitro Techniques; Ion Channel Gating; Male; Membrane Potentials; Myocardial Infarction; Myocardial Ischemia; Perfusion; Potassium Channels; Pyrroles; Vasodilator Agents | 1995 |
KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Topics: Animals; Anti-Arrhythmia Agents; Benzopyrans; Coronary Circulation; Coronary Disease; Cromakalim; Glyburide; Heart; Ion Channel Gating; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Potassium Channels; Pyridines; Pyrroles; Rats; Rats, Wistar; Ventricular Fibrillation | 1995 |
Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution.
Topics: Adenosine Triphosphate; Animals; Benzopyrans; Cardioplegic Solutions; Cromakalim; Guanidines; Heart; Male; Myocardial Ischemia; Potassium Channels; Pyrroles; Rats; Rats, Sprague-Dawley | 1995 |
Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.
Topics: Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dose-Response Relationship, Drug; Glyburide; Male; Myocardial Ischemia; Myocardium; Perfusion; Phenylisopropyladenosine; Potassium Channels; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Xanthines | 1996 |
Comparative cardioprotective effects of cromakalim and diltiazem in ischemic hypertrophied rat hearts.
Topics: Animals; Benzopyrans; Blood Pressure; Cardiomegaly; Cromakalim; Diltiazem; Heart; Heart Rate; L-Lactate Dehydrogenase; Male; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Ventricular Function, Left | 1996 |
A comparison between the effects of BMS-180448, a novel K+ channel opener, and cromakalim in rat and dog.
Topics: Animals; Anti-Arrhythmia Agents; Aorta, Thoracic; Benzopyrans; Blood Pressure; Cardiotonic Agents; Cromakalim; Dogs; Electrophysiology; Guanidines; Heart; Heart Conduction System; Heart Rate; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Myocardial Ischemia; Potassium Channels; Pyrroles; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Refractory Period, Electrophysiological; Species Specificity | 1995 |
Effects of cromakalim and glibenclamide in ischemic and reperfused hearts.
Topics: Animals; Anti-Arrhythmia Agents; Benzopyrans; Cromakalim; Diabetes Mellitus, Experimental; Glyburide; In Vitro Techniques; Male; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Sprague-Dawley | 1996 |
Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K+c channels.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dogs; Enzyme Activation; Glyburide; Heart; Hemodynamics; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Recurrence | 1996 |
Acute simulated ischaemia produces both inhibition and activation of K+ currents in isolated ventricular myocytes.
Topics: Action Potentials; Animals; Benzopyrans; Cromakalim; Hydrogen-Ion Concentration; Ischemic Preconditioning, Myocardial; Myocardial Ischemia; Myocardium; Patch-Clamp Techniques; Potassium Channels; Pyrroles; Rats; Sodium-Potassium-Exchanging ATPase | 1996 |
Effects of tolbutamide on ATP-sensitive K+ channels from human right atrial cardiac myocytes.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Atrial Function, Right; Benzopyrans; Child; Cromakalim; Drug Interactions; Female; Heart Atria; Humans; Hypoglycemic Agents; Kinetics; Male; Membrane Potentials; Middle Aged; Myocardial Ischemia; Myocardium; Potassium Channels; Pyrroles; Sensitivity and Specificity; Tolbutamide | 1997 |
Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Benzopyrans; Coronary Circulation; Cromakalim; Decanoic Acids; Dose-Response Relationship, Drug; Glyburide; Hydrogen-Ion Concentration; Hydroxy Acids; Hypoglycemic Agents; In Vitro Techniques; Lactates; Magnetic Resonance Spectroscopy; Male; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Phosphorus Isotopes; Pyrroles; Rats; Rats, Sprague-Dawley | 1997 |
Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts.
Topics: Animals; Arrhythmias, Cardiac; Benzopyrans; Calcium; Cromakalim; Diabetes Mellitus, Experimental; Heart; Magnesium; Male; Myocardial Ischemia; Myocardial Reperfusion; Potassium Channels; Pyrroles; Rats; Rats, Sprague-Dawley; Sodium; Streptozocin | 1997 |
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome | 1998 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Recurrence | 1999 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
A pyrroline derivative of mexiletine offers marked protection against ischemia/reperfusion-induced myocardial contractile dysfunction.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Binding, Competitive; Coronary Circulation; Dose-Response Relationship, Drug; Female; Hydroxyl Radical; Mexiletine; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Ouabain; Oxidation-Reduction; Pyrroles; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Ventricular Dysfunction, Left; Ventricular Pressure | 2000 |
Effect of SMP-300, a new Na+/H+ exchange inhibitor, on myocardial ischemia and experimental angina models in rats.
Topics: Amiloride; Angina Pectoris; Animals; Azocines; Blood Pressure; Disease Models, Animal; Electrocardiography; Heart; Heart Rate; Isoproterenol; Male; Myocardial Ischemia; Myocardium; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley; Sodium-Hydrogen Exchangers; Vasopressins | 2000 |
[Meeting report. "MIRACL" study of "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering"].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Patient Selection; Pyrroles; Treatment Outcome | 2000 |
Influence of KATP channel modulation on net potassium efflux from ischaemic mammalian cardiac tissue.
Topics: Action Potentials; Animals; Barium; Benzopyrans; Cromakalim; Glyburide; Guinea Pigs; Hydrogen-Ion Concentration; Muscles; Myocardial Ischemia; Oxygen; Papillary Muscles; Potassium; Potassium Channels; Pyrroles; Tolbutamide; Vasodilator Agents | 1992 |
Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration.
Topics: Action Potentials; Animals; Benzopyrans; Blood Pressure; Coronary Circulation; Coronary Vessels; Cromakalim; Dogs; Glyburide; Myocardial Contraction; Myocardial Ischemia; Pyrroles; Vasodilator Agents | 1992 |
Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia.
Topics: Animals; Benzopyrans; Blood Pressure; Coronary Circulation; Coronary Vessels; Cromakalim; Glyburide; Heart Arrest, Induced; Myocardial Contraction; Myocardial Ischemia; Potassium Channels; Pyrroles; Rats; Rats, Wistar; Vasodilator Agents | 1992 |
KATP channel opening and cardioprotection.
Topics: Benzopyrans; Cromakalim; Humans; Myocardial Ischemia; Potassium Channels; Pyrroles; Vasodilator Agents | 1992 |
Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Female; Heart; Heart Ventricles; In Vitro Techniques; Male; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Parasympatholytics; Potassium; Potassium Channels; Pyrroles; Rabbits; Vasodilator Agents | 1992 |